Business · 15/01/2025Updated: 10/17/2026 · 1 min read
FDA Awards Priority Review Voucher to Novo Nordisk for Rare Pediatric Disease Product ALHEMO
Summary
The FDA has awarded a priority review voucher to Novo Nordisk, Inc. for its rare pediatric disease product ALHEMO (concizumab-mtci), approved on December 20, 2024.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →